The p160 ER co-regulators predict outcome in ER negative breast cancer

Breast Cancer Res Treat. 2012 Jan;131(2):463-72. doi: 10.1007/s10549-011-1426-1. Epub 2011 Mar 9.

Abstract

The SRC family of ER co-regulators are frequently overexpressed in breast cancer. Overexpression of AIB1 appears to be linked to hormone resistance in HER2 positive breast cancer. However, the role of these co-regulators in ER negative disease is poorly understood. SRC1, SRC2 and AIB1 expression was determined by immunohistochemical analysis of tissue microarrays constructed from tumours within the Edinburgh Breast Conservation Series (BCS). The BCS represents a fully documented consecutive cohort of 1,812 patients treated by breast conservation surgery in a single institution. Our results demonstrate tumours that overexpress both HER2 and AIB1 were associated with markedly reduced relapse free, distant relapse free and overall survival compared to HER2 and AIB1 only overexpressing tumours irrespective of ER status. In ER negative disease both SRC1 and AIB1 were linked to early relapse and death. The SRC family of ER co-regulators is involved in early relapse and resistance in both ER negative and ER positive breast cancer challenging the conventional concept that this effect is mediated solely via the ER.

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Middle Aged
  • Nuclear Receptor Coactivator 3 / metabolism
  • Nuclear Receptor Coactivators / metabolism*
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / analysis*
  • Survival Analysis
  • Tissue Array Analysis

Substances

  • Nuclear Receptor Coactivators
  • Receptors, Estrogen
  • Nuclear Receptor Coactivator 3
  • Receptor, ErbB-2